Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies.
Glez-Vaz J, Azpilikueta A, Olivera I, Cirella A, Teijeira A, Ochoa MC, Alvarez M, Eguren-Santamaria I, Luri-Rey C, Rodriguez-Ruiz ME, Nie X, Chen L, Guedan S, Sanamed MF, Perez Gracia JL, Melero I. Glez-Vaz J, et al. Among authors: guedan s. J Immunother Cancer. 2022 Mar;10(3):e003532. doi: 10.1136/jitc-2021-003532. J Immunother Cancer. 2022. PMID: 35236742 Free PMC article.
Immobilizing A Moving Target: CAR T Cells Hit CD22.
Guedan S, Delgado J. Guedan S, et al. Clin Cancer Res. 2019 Sep 1;25(17):5188-5190. doi: 10.1158/1078-0432.CCR-19-1649. Epub 2019 Jul 2. Clin Cancer Res. 2019. PMID: 31266831
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.
Blanco B, Ramírez-Fernández Á, Bueno C, Argemí-Muntadas L, Fuentes P, Aguilar-Sopeña Ó, Gutierrez-Agüera F, Zanetti SR, Tapia-Galisteo A, Díez-Alonso L, Segura-Tudela A, Castellà M, Marzal B, Betriu S, Harwood SL, Compte M, Lykkemark S, Erce-Llamazares A, Rubio-Pérez L, Jiménez-Reinoso A, Domínguez-Alonso C, Neves M, Morales P, Paz-Artal E, Guedan S, Sanz L, Toribio ML, Roda-Navarro P, Juan M, Menéndez P, Álvarez-Vallina L. Blanco B, et al. Among authors: guedan s. Cancer Immunol Res. 2022 Apr 1;10(4):498-511. doi: 10.1158/2326-6066.CIR-21-0853. Cancer Immunol Res. 2022. PMID: 35362043 Free PMC article.
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?
Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, Casucci M, De Angelis B, Donnadieu E, Espie D, Greco B, Groen R, Huppa JB, Kantari-Mimoun C, Laugel B, Mantock M, Markman JL, Morris E, Quintarelli C, Rade M, Reiche K, Rodriguez-Garcia A, Rodriguez-Madoz JR, Ruggiero E, Themeli M, Hudecek M, Marchiq I. Guedan S, et al. J Immunother Cancer. 2022 May;10(5):e003487. doi: 10.1136/jitc-2021-003487. J Immunother Cancer. 2022. PMID: 35577501 Free PMC article. Review.
mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy.
Olivera I, Bolaños E, Gonzalez-Gomariz J, Hervas-Stubbs S, Mariño KV, Luri-Rey C, Etxeberria I, Cirella A, Egea J, Glez-Vaz J, Garasa S, Alvarez M, Eguren-Santamaria I, Guedan S, Sanmamed MF, Berraondo P, Rabinovich GA, Teijeira A, Melero I. Olivera I, et al. Among authors: guedan s. Cell Rep Med. 2023 Mar 17;4(3):100978. doi: 10.1016/j.xcrm.2023.100978. Online ahead of print. Cell Rep Med. 2023. PMID: 36933554 Free PMC article.
Emerging Cellular Therapies for Cancer.
Guedan S, Ruella M, June CH. Guedan S, et al. Annu Rev Immunol. 2019 Apr 26;37:145-171. doi: 10.1146/annurev-immunol-042718-041407. Epub 2018 Dec 10. Annu Rev Immunol. 2019. PMID: 30526160 Free PMC article. Review.
Analysis of CAR-Mediated Tonic Signaling.
Calderon H, Mamonkin M, Guedan S. Calderon H, et al. Among authors: guedan s. Methods Mol Biol. 2020;2086:223-236. doi: 10.1007/978-1-0716-0146-4_17. Methods Mol Biol. 2020. PMID: 31707680
37 results